Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure

Antiviral Research

Volumn 121, Issue , 2015, Pages 152-159

  Chang, Jinhong ^a   Guo, Ju Tao ^a  

^a BARUCH S BLUMBERG INSTITUTE   (United States)

Author keywords

Cytokine; Hepatitis B virus; Innate immune response; Pattern recognition receptor agonist

Indexed keywords

ANTIVIRUS AGENT; CYTOKINE; GS 9620; HEPATITIS B VACCINE; INTERFERON; NUCLEOSIDE ANALOG; PATTERN RECOGNITION RECEPTOR; PATTERN RECOGNITION RECEPTOR AGONIST; STING AGONIST; TETRACYCLINE; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VADIMEZAN; VASCULAR TARGETING AGENT; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; DRUG POTENCY; FUNCTIONAL STATUS; HEPATITIS B VIRUS; HUMAN; INFECTION CONTROL; INNATE IMMUNITY; LIVER CELL; MUCOSAL IMMUNITY; NONHUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; VACCINATION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION; AGONISTS; ANIMAL; DISEASE MODEL; HEPATITIS B, CHRONIC; PRECLINICAL STUDY; TREATMENT OUTCOME;

HEPATITIS B VIRUS; STEALTH VIRUS;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HEPATITIS B, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; RECEPTORS, PATTERN RECOGNITION; TREATMENT OUTCOME;

EID: 84938368956     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.07.006     Document Type: Review

References (80)

1. S. Akira, S. Uematsu, and O. Takeuchi Pathogen recognition and innate immunity Cell 124 4 2006 783 801
2. L. Allweiss, T. Volz, M. Lutgehetmann, K. Giersch, T. Bornscheuer, A.W. Lohse, J. Petersen, H. Ma, K. Klumpp, S.P. Fletcher, and M. Dandri Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration J. Hepatol. 60 3 2013 500 507
3. R.P. Beasley, L.Y. Hwang, G.C. Lee, C.C. Lan, C.H. Roan, F.Y. Huang, and C.L. Chen Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine Lancet 2 8359 1983 1099 1102
4. L. Belloni, L. Allweiss, F. Guerrieri, N. Pediconi, T. Volz, T. Pollicino, J. Petersen, G. Raimondo, M. Dandri, and M. Levrero IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome J. Clin. Invest. 122 2 2012 529 537
5. A. Bertoletti, and C. Ferrari Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection Gut 61 12 2011 1754 1764
6. A. Bertoletti, and A. Gehring Therapeutic vaccination and novel strategies to treat chronic HBV infection Expert Rev. Gastroenterol. Hepatol. 3 5 2009 561 569
7. A. Bertoletti, and A.J. Gehring Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLoS Pathog. 9 12 2013 e1003784
8. D.L. Burdette, and R.E. Vance STING and the innate immune response to nucleic acids in the cytosol Nat. Immunol. 14 1 2013 19 26
9. J. Chang, T.M. Block, and J.T. Guo The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy Antiviral Res. 96 3 2012 405 413
10. J. Chang, F. Guo, X. Zhao, and J.-T. Guo Therapeutic strategies for a functional cure of chronic hepatitis B virus infection Acta Pharm. Sin. B 4 4 2014 248 257
11. H.H. Chou, W.H. Chien, L.L. Wu, C.H. Cheng, C.H. Chung, J.H. Horng, Y.H. Ni, H.T. Tseng, D. Wu, X. Lu, H.Y. Wang, P.J. Chen, and D.S. Chen Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota Proc. Natl. Acad. Sci. U.S.A. 112 7 2015 2175 2180
12. T.W. Dubensky Jr. , D.B. Kanne, and M.L. Leong Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants Ther. Adv. Vaccines 1 4 2013 131 143
13. C. Dunn, D. Peppa, P. Khanna, G. Nebbia, M. Jones, N. Brendish, R.M. Lascar, D. Brown, R.J. Gilson, R.J. Tedder, G.M. Dusheiko, M. Jacobs, P. Klenerman, and M.K. Maini Temporal analysis of early immune responses in patients with acute hepatitis B virus infection Gastroenterology 137 4 2009 1289 1300
14. P. Fisicaro, C. Valdatta, C. Boni, M. Massari, C. Mori, A. Zerbini, A. Orlandini, L. Sacchelli, G. Missale, and C. Ferrari Early kinetics of innate and adaptive immune responses during hepatitis B virus infection Gut 58 7 2009 974 982
15. S.P. Fletcher, D.J. Chin, Y. Ji, A.L. Iniguez, B. Taillon, D.C. Swinney, P. Ravindran, D.T. Cheng, H. Bitter, U. Lopatin, H. Ma, K. Klumpp, and S. Menne Transcriptomic analysis of the woodchuck model of chronic hepatitis B Hepatology 56 3 2012 820 830
16. A. Fosdick, J. Zheng, S. Pflanz, C.R. Frey, J. Hesselgesser, R.L. Halcomb, G. Wolfgang, and D.B. Tumas Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses J. Pharmacol. Exp. Ther. 348 1 2014 96 105
17. J. Fu, D.B. Kanne, M. Leong, L.H. Glickman, S.M. McWhirter, E. Lemmens, K. Mechette, J.J. Leong, P. Lauer, W. Liu, K.E. Sivick, Q. Zeng, K.C. Soares, L. Zheng, D.A. Portnoy, J.J. Woodward, D.M. Pardoll, T.W. Dubensky Jr., and Y. Kim STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade Sci. Transl. Med. 7 283 2015 283ra52
18. E.J. Gane, Y.S. Lim, S.C. Gordon, K. Visvanathan, E. Sicard, R.N. Fedorak, S. Roberts, B. Massetto, Z. Ye, S. Pflanz, K.L. Garrison, A. Gaggar, G. Mani Subramanian, J.G. McHutchison, S. Kottilil, B. Freilich, C.S. Coffin, W. Cheng, and Y.J. Kim The oral Toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection J. Hepatol. 2015
19. D. Gao, J. Wu, Y.T. Wu, F. Du, C. Aroh, N. Yan, L. Sun, and Z.J. Chen Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses Science 341 6148 2013 903 906
20. O. Godon, H. Fontaine, S. Kahi, J. Meritet, D. Scott-Algara, S. Pol, M. Michel, and M. Bourgine Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues Mol. Ther. 22 3 2013 675 684
21. P.M. Gray, G. Forrest, T. Wisniewski, G. Porter, D.C. Freed, J.A. DeMartino, D.M. Zaller, Z. Guo, J. Leone, T.M. Fu, and K.A. Vora Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities Cell. Immunol. 278 1-2 2012 113 119
22. L.G. Guidotti, T. Ishikawa, M.V. Hobbs, B. Matzke, R. Schreiber, and F.V. Chisari Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes Immunity 4 1 1996 25 36
23. L.G. Guidotti, R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F.V. Chisari Viral clearance without destruction of infected cells during acute HBV infection Science 284 5415 1999 825 829 (in process citation)
24. F. Guo, Y. Han, X. Zhao, J. Wang, F. Liu, C. Xu, L. Wei, J.D. Jiang, T.M. Block, J.T. Guo, and J. Chang STING agonists induce an innate antiviral immune response against hepatitis B virus Antimicrob. Agents Chemother. 59 2 2015 1273 1281
25. M.C. Hanson, M.P. Crespo, W. Abraham, K.D. Moynihan, G.L. Szeto, S.H. Chen, M.B. Melo, S. Mueller, and D.J. Irvine Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants J. Clin. Invest. 2015
26. W.L. Heyward, M. Kyle, J. Blumenau, M. Davis, K. Reisinger, M.L. Kabongo, S. Bennett, R.S. Janssen, H. Namini, and J.T. Martin Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age Vaccine 31 46 2013 5300 5305
27. M. Hong, E. Sandalova, D. Low, A.J. Gehring, S. Fieni, B. Amadei, S. Urbani, Y.S. Chong, E. Guccione, and A. Bertoletti Trained immunity in newborn infants of HBV-infected mothers Nat. Commun. 6 2015 6588
28. L.R. Huang, Y.A. Gabel, S. Graf, S. Arzberger, C. Kurts, M. Heikenwalder, P.A. Knolle, and U. Protzer Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice Gastroenterology 142 7 2012 (pp. 1447-50.e3)
29. L.R. Huang, D. Wohlleber, F. Reisinger, C.N. Jenne, R.L. Cheng, Z. Abdullah, F.A. Schildberg, M. Odenthal, H.P. Dienes, N. van Rooijen, E. Schmitt, N. Garbi, M. Croft, C. Kurts, P. Kubes, U. Protzer, M. Heikenwalder, and P.A. Knolle Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection Nat. Immunol. 14 6 2013 574 583
30. H. Ishikawa, and G.N. Barber STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling Nature 455 7213 2008 674 678
31. M. Isogawa, M.D. Robek, Y. Furuichi, and F.V. Chisari Toll-like receptor signaling inhibits hepatitis B virus replication in vivo J. Virol. 79 11 2005 7269 7272
32. A. Iwasaki, and R. Medzhitov Control of adaptive immunity by the innate immune system Nat. Immunol. 16 4 2015 343 353
33. R.S. Janssen, R. Mangoo-Karim, P.E. Pergola, M. Girndt, H. Namini, S. Rahman, S.R. Bennett, W.L. Heyward, and J.T. Martin Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease Vaccine 31 46 2013 5306 5313
34. J. Jo, A.T. Tan, J.E. Ussher, E. Sandalova, X.Z. Tang, A. Tan-Garcia, N. To, M. Hong, A. Chia, U.S. Gill, P.T. Kennedy, K.C. Tan, K.H. Lee, G. De Libero, A.J. Gehring, C.B. Willberg, P. Klenerman, and A. Bertoletti Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver PLoS Pathog. 10 6 2014 e1004210
35. H. Kanzler, F.J. Barrat, E.M. Hessel, and R.L. Coffman Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists Nat. Med. 13 5 2007 552 559
36. P.A. Knolle, and R. Thimme Hepatic immune regulation and its involvement in viral hepatitis infection Gastroenterology 146 5 2014 1193 1207
37. H. Komatsu, A. Inui, T. Sogo, E. Hiejima, A. Tateno, P. Klenerman, and T. Fujisawa Cellular immunity in children with successful immunoprophylactic treatment for mother-to-child transmission of hepatitis B virus BMC Infect. Dis. 10 2010 103
38. A.D. Kosinska, E. Zhang, L. Johrden, J. Liu, P.L. Seiz, X. Zhang, Z. Ma, T. Kemper, M. Fiedler, D. Glebe, O. Wildner, U. Dittmer, M. Lu, and M. Roggendorf Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model PLoS Pathog. 9 6 2013 e1003391
39. L. Koumbi, A. Bertoletti, V. Anastasiadou, M. Machaira, W. Goh, N.G. Papadopoulos, D.A. Kafetzis, and V. Papaevangelou Hepatitis B-specific T helper cell responses in uninfected infants born to HBsAg+/HBeAg- mothers Cell. Mol. Immunol. 7 6 2010 454 458
40. R.E. Lanford, B. Guerra, D. Chavez, L. Giavedoni, V.L. Hodara, K.M. Brasky, A. Fosdick, C.R. Frey, J. Zheng, G. Wolfgang, R.L. Halcomb, and D.B. Tumas GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees Gastroenterology 144 7 2013 1508 1517 (pp. 1517.e1-10)
41. E. Lawitz, D. Gruener, T. Marbury, J. Hill, L. Webster, D. Hassman, A.H. Nguyen, S. Pflanz, E. Mogalian, A. Gaggar, B. Massetto, G.M. Subramanian, J.G. McHutchison, I.M. Jacobson, B. Freilich, and M. Rodriguez-Torres Safety, pharmacokinetics and pharmacodynamics of the oral Toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C Antivir. Ther. 2014
42. W.M. Lee Hepatitis B virus infection N. Engl. J. Med. 337 24 1997 1733 1745
43. T.J. Liang Hepatitis B: the virus and disease Hepatology 49 5 Suppl. 2009 S13 S21
44. G. Liang, G. Liu, K. Kitamura, Z. Wang, S. Chowdhury, A.M. Monjurul, K. Wakae, M. Koura, M. Shimadu, K. Kinoshita, and M. Muramatsu TGF-beta suppression of HBV RNA through AID-dependent recruitment of an RNA exosome complex PLoS Pathog. 11 4 2015 e1004780
45. Y.F. Liaw Impact of therapy on the outcome of chronic hepatitis B Liver Int. 33 Suppl. 1 2013 111 115
46. F. Liu, M. Campagna, Y. Qi, X. Zhao, F. Guo, C. Xu, S. Li, W. Li, T.M. Block, J. Chang, and J.T. Guo Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes PLoS Pathog. 9 9 2013 e1003613
47. J. Liu, A. Kosinska, M. Lu, and M. Roggendorf New therapeutic vaccination strategies for the treatment of chronic hepatitis B Virol. Sin. 29 1 2014 10 16
48. J. Liu, E. Zhang, Z. Ma, W. Wu, A. Kosinska, X. Zhang, I. Moller, P. Seiz, D. Glebe, B. Wang, D. Yang, M. Lu, and M. Roggendorf Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection PLoS Pathog. 10 1 2014 e1003856
49. S. Luangsay, M. Ait-Goughoulte, M. Michelet, O. Floriot, M. Bonnin, M. Gruffaz, M. Rivoire, S. Fletcher, H. Javanbakht, J. Lucifora, F. Zoulim, and D. Durantel Expression and functionality of Toll- and RIG-like receptors in HepaRG cells J. Hepatol. 2015
50. J. Lucifora, Y. Xia, F. Reisinger, K. Zhang, D. Stadler, X. Cheng, M.F. Sprinzl, H. Koppensteiner, Z. Makowska, T. Volz, C. Remouchamps, W.M. Chou, W.E. Thasler, N. Huser, D. Durantel, T.J. Liang, C. Munk, M.H. Heim, J.L. Browning, E. Dejardin, M. Dandri, M. Schindler, M. Heikenwalder, and U. Protzer Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA Science 343 6176 2014 1221 1228
51. M. Lutgehetmann, T. Bornscheuer, T. Volz, L. Allweiss, J.H. Bockmann, J.M. Pollok, A.W. Lohse, J. Petersen, and M. Dandri Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice Gastroenterology 140 7 2011 2074 2783 (pp. 2083.e1-2)
52. C.O. Mackie, J.A. Buxton, S. Tadwalkar, and D.M. Patrick Hepatitis B immunization strategies: timing is everything CMAJ 180 2 2009 196 202
53. A. Marchant, V. Appay, M. Van Der Sande, N. Dulphy, C. Liesnard, M. Kidd, S. Kaye, O. Ojuola, G.M. Gillespie, A.L. Vargas Cuero, V. Cerundolo, M. Callan, K.P. McAdam, S.L. Rowland-Jones, C. Donner, A.J. McMichael, and H. Whittle Mature CD8(+) T lymphocyte response to viral infection during fetal life J. Clin. Invest. 111 11 2003 1747 1755
54. S. Menne, and P.J. Cote The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection World J. Gastroenterol. 13 1 2007 104 124
55. S. Menne, D.B. Tumas, K.H. Liu, L. Thampi, D. AlDeghaither, B.H. Baldwin, C.A. Bellezza, P.J. Cote, J. Zheng, R. Halcomb, A. Fosdick, S.P. Fletcher, S. Daffis, L. Li, P. Yue, G.H. Wolfgang, and B.C. Tennant Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B J. Hepatol. 62 6 2015 1237 1245
56. J.J. Ott, G.A. Stevens, J. Groeger, and S.T. Wiersma Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity Vaccine 30 12 2012 2212 2219
57. L.J. Pallett, U.S. Gill, A. Quaglia, L.V. Sinclair, M. Jover-Cobos, A. Schurich, K.P. Singh, N. Thomas, A. Das, A. Chen, G. Fusai, A. Bertoletti, D.A. Cantrell, P.T. Kennedy, N.A. Davies, M. Haniffa, and M.K. Maini Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells Nat. Med. 2015
58. S.R. Paludan, and A.G. Bowie Immune sensing of DNA Immunity 38 5 2013 870 880
59. R. Perrillo Benefits and risks of interferon therapy for hepatitis B Hepatology 49 5 Suppl. 2009 S103 S111
60. J. Publicover, A. Goodsell, S. Nishimura, S. Vilarinho, Z.E. Wang, L. Avanesyan, R. Spolski, W.J. Leonard, S. Cooper, and J.L. Baron IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B J. Clin. Invest. 121 3 2011 1154 1162
61. J. Publicover, A. Gaggar, S. Nishimura, C.M. Van Horn, A. Goodsell, M.O. Muench, R.L. Reinhardt, N. van Rooijen, A.E. Wakil, M. Peters, J.G. Cyster, D.J. Erle, P. Rosenthal, S. Cooper, and J.L. Baron Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B J. Clin. Invest. 123 9 2013 3728 3739
62. S. Sato, K. Li, T. Kameyama, T. Hayashi, Y. Ishida, S. Murakami, T. Watanabe, S. Iijima, Y. Sakurai, K. Watashi, S. Tsutsumi, Y. Sato, H. Akita, T. Wakita, C.M. Rice, H. Harashima, M. Kohara, Y. Tanaka, and A. Takaoka The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus Immunity 42 1 2015 123 132
63. A. Shlomai, R.E. Schwartz, V. Ramanan, A. Bhatta, Y.P. de Jong, S.N. Bhatia, and C.M. Rice Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems Proc. Natl. Acad. Sci. U.S.A. 111 33 2015 12193 12198
64. J. Summers, A.R. Jilbert, W. Yang, C.E. Aldrich, J. Saputelli, S. Litwin, E. Toll, and W.S. Mason Hepatocyte turnover during resolution of a transient hepadnaviral infection Proc. Natl. Acad. Sci. U.S.A. 100 20 2003 11652 11659
65. O. Takeuchi, and S. Akira Pattern recognition receptors and inflammation Cell 140 6 2010 805 820
66. R. Tohidi-Esfahani, K. Vickery, and Y. Cossart The early host innate immune response to duck hepatitis B virus infection J. Gen. Virol. 91 Pt 2 2010 509 520
67. D. Vermijlen, M. Brouwer, C. Donner, C. Liesnard, M. Tackoen, M. Van Rysselberge, N. Twite, M. Goldman, A. Marchant, and F. Willems Human cytomegalovirus elicits fetal gammadelta T cell responses in utero J. Exp. Med. 207 4 2010 807 821
68. Y. Wang, K. Chen, Z. Wu, Y. Liu, S. Liu, Z. Zou, S.H. Chen, and C. Qu Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice Int. J. Infect. Dis. 29 2014 31 36
69. K. Watashi, G. Liang, M. Iwamoto, H. Marusawa, N. Uchida, T. Daito, K. Kitamura, M. Muramatsu, H. Ohashi, T. Kiyohara, R. Suzuki, J. Li, S. Tong, Y. Tanaka, K. Murata, H. Aizaki, and T. Wakita Interleukin-1 and tumor necrosis factor-alpha trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID) J. Biol. Chem. 288 44 2013 31715 31727
70. C. Watts, M.A. West, and R. Zaru TLR signalling regulated antigen presentation in dendritic cells Curr. Opin. Immunol. 22 1 2010 124 130
71. S.F. Wieland, and F.V. Chisari Stealth and cunning: hepatitis B and hepatitis C viruses J. Virol. 79 15 2005 9369 9380
72. S. Wieland, R. Thimme, R.H. Purcell, and F.V. Chisari Genomic analysis of the host response to hepatitis B virus infection Proc. Natl. Acad. Sci. U.S.A. 101 17 2004 6669 6674
73. S.F. Wieland, A. Eustaquio, C. Whitten-Bauer, B. Boyd, and F.V. Chisari Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids Proc. Natl. Acad. Sci. U.S.A. 102 28 2005 9913 9917
74. J. Wu, M. Lu, Z. Meng, M. Trippler, R. Broering, A. Szczeponek, F. Krux, U. Dittmer, M. Roggendorf, G. Gerken, and J.F. Schlaak Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice Hepatology 46 6 2007 1769 1778
75. J. Wu, S. Huang, X. Zhao, M. Chen, Y. Lin, Y. Xia, C. Sun, X. Yang, J. Wang, Y. Guo, J. Song, E. Zhang, B. Wang, X. Zheng, J.F. Schlaak, M. Lu, and D. Yang Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model J. Virol. 88 18 2014 10421 10431
76. K. Wursthorn, M. Lutgehetmann, M. Dandri, T. Volz, P. Buggisch, B. Zollner, T. Longerich, P. Schirmacher, F. Metzler, M. Zankel, C. Fischer, G. Currie, C. Brosgart, and J. Petersen Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B Hepatology 44 3 2006 675 684
77. C. Xu, H. Guo, X.B. Pan, R. Mao, W. Yu, X. Xu, L. Wei, J. Chang, T.M. Block, and J.T. Guo Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus J. Virol. 84 18 2010 9332 9340
78. D.Z. Xu, X.Y. Wang, X.L. Shen, G.Z. Gong, H. Ren, L.M. Guo, A.M. Sun, M. Xu, L.J. Li, X.H. Guo, Z. Zhen, H.F. Wang, H.Y. Gong, C. Xu, N. Jiang, C. Pan, Z.J. Gong, J.M. Zhang, J. Shang, J. Xu, Q. Xie, T.F. Wu, W.X. Huang, Y.G. Li, Z.H. Yuan, B. Wang, K. Zhao, and Y.M. Wen Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings J. Hepatol. 59 3 2013 450 456
79. D. Yang, L. Liu, D. Zhu, H. Peng, L. Su, Y.X. Fu, and L. Zhang A mouse model for HBV immunotolerance and immunotherapy Cell. Mol. Immunol. 11 1 2014 71 78
80. S. Zeissig, K. Murata, L. Sweet, J. Publicover, Z. Hu, A. Kaser, E. Bosse, J. Iqbal, M.M. Hussain, K. Balschun, C. Rocken, A. Arlt, R. Gunther, J. Hampe, S. Schreiber, J.L. Baron, D.B. Moody, T.J. Liang, and R.S. Blumberg Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity Nat. Med. 18 7 2012 1060 1068